CANCURE LLC
Biotech · Private
Complex molecule composed of a soluble peptide and binding agent for ex vivo NK and CD8 T cell expansion to enhance persistence and efficacy in solid tumor immunotherapy
- Grants
- $2.6M
- 6 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 4
- 1 granted · 3 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201620182020202220242026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Optimization of a novel cancer immunotherapeutic antibody for human use | $299,994 | |
| Federal grant | Department of Health and Human Services · Phase I · Optimization of a novel cancer immunotherapeutic antibody for human use | $349,994 | |
| Federal grant | Department of Health and Human Services · Phase I · Optimization of a novel cancer immunotherapeutic antibody for human use | $50,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a novel class of immunotherapeutic antibody for metastatic prostate cancer | $818,940 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a novel class of immunotherapeutic antibody for metastatic prostate cancer | $681,039 | |
| Federal grant | Department of Health and Human Services · Phase I · Feasibility study of a novel NK and CD8 T cells stimulating agent | $399,444 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2968 | ReNeuroGen LLC | — | — |
| 2969 | The NanoMedicines Innovation Network | — | — |
| 2970 | Kartos Therapeutics | — | — |
| 2971 | CANCURE LLC | — | — |
| 2972 | ADMA BIOLOGICS, INC. | — | — |
| 2973 | Loop East Community Improvement District | — | $1.6M |
| 2974 | ACPHARIS | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- MIC Antibodies and Binding Agents and Methods of Using the Sameapplication
- MIC Antibodies and Binding Agents and Methods of Using the Samegranted
- Mic Antibodies And Binding Agents And Methods Of Using The Sameapplication
- Mic Antibodies And Binding Agents And Methods Of Using The Sameapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.